Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice

Li, Xiuzhen; Wang, Xiaohu; Xia, Lijun; Weng, Ya-Biao; Hernández, Jorge A.; Tu, Liqing; Li, Lutao; Li, Shoujun; Yuan, Zihao

doi:10.1186/s12879-015-0815-1

Cited by 22 publications

(20 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ppoly2-CAV2-ΔE3 vector is mainly composed of the partial E3 region of CAV-2, human cytomegalovirus (hCMV) immediate-early gene promoter, polyA and the SV40 early mRNA polyadenylation signal. This vector was used for the recombined vaccine [ 49 ].…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines

Zhou

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Canine influenza virus (CIV) has the potential risk to spread in different areas and dog types. Thus, there is a growing need to develop an effective vaccine to control CIV disease. Here, we developed three vaccine candidates: 1) a recombinant pVAX1 vector expressing H3N2 CIV hemagglutinin (pVAX1-HA); 2) a live attenuated canine adenovirus type 2 expressing H3N2 CIV hemagglutinin (rCAV2-HA); and 3) an inactivated H3N2 CIV (A/canine/Guangdong/01/2006 (H3N2)). Mice received an initial intramuscular immunization that followed two booster injections at 2 and 4 weeks post-vaccination (wpv). The splenic lymphocytes were collected to assess the immune responses at 6 wpv. The protective efficacy was evaluated by challenging H3N2 CIV after vaccination (at 6 wpv). Our results demonstrated that all three vaccine candidates elicited cytokine and antibody responses in mice. The rCAV2-HA vaccine and the inactivated vaccine generated efficient protective efficacy in mice, whereas limited protection was provided by the pVAX1-HA DNA vaccine. Therefore, both the rCAV2-HA live recombinant virus and the inactivated CIV could be used as potential novel vaccines against H3N2CIV. This study provides guidance for choosing the most appropriate vaccine for the prevention and control of CIV disease.

show abstract

Section: Methodsmentioning

confidence: 99%

“…In addition, we generated the recombinant canine adenovirus type 2 virus (rCAV2-HA) expressing H3N2 CIV HA protein as previously described [ 49 ]. Briefly, the HA gene (A/canine/Guangdong/01/2006 (H3N2)) was inserted into the ppoly2-CAV2-ΔE3 vector (ppoly2-CAV2-ΔE3-HA).…”

Section: Methodsmentioning

confidence: 99%

Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines

Zhou

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Two mice groups were injected intraperitoneally with 0.2 mL of physiological saline containing 1 × 10 2 T. gondii tachyzoite RH strain (type I) and labelled as infected groups. In our previous work, we have previously studied the optimal number of RH strain infections per mouse, in order to minimize damage by T. gondii infection [17]. Meanwhile, the control group was injected with an equal dose of physiological saline.…”

Section: Animals and Experiments Set-upmentioning

confidence: 99%

Transcriptome Analysis of Testes and Uterus: Reproductive Dysfunction Induced by Toxoplasma gondii in Mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Toxoplasma gondii (T. gondii) infection in female mammals during pregnancy can result in poor pregnancy. Similarly, it can result in male reproductive disorders in male mammals. Although the testes and uterus have very different biological makeup, they are still both attacked by T. gondii resulting in reproductive dysfunctions. We hypothesized that there are significant common genes in the testes and uterus that interact with T. gondii. Finding out and studying these genes is vital to understand the infection mechanism of T. gondii and the induced disease pathogenesis. To achieve this goal, we built a mice model of acute infection with T. gondii and the testes and uterus of the mice were sequenced by RNA-Seq. A total of 291 and 679 significantly differently expressed genes (DEGs) were obtained from the testes and the uterus, respectively. In the Gene Ontology (GO) analysis, part of the DEGs in the testes and uterus were related to 35 GO functions. When compared with the KEGG database, seven pathways affecting both the testes and uterus during the course of T. gondii infection were identified. In addition, Toxoplasmosis can significantly affect the expression of Nlrp5 and Insc leading to negative outcomes in the host. On the other hand, the host regulates Gbp7, Gbp2b, and Ifit3 to defend against T. gondii infection.

show abstract

“…Adenovirus, which can penetrate host cells delivering vaccine antigen to antigen-presenting cells (APCs) and elicit vigorous and sustained T-cell responses, is a promising T. gondii vaccine vector and can be used effectively to transport immunogens [27]. Recent studies have also found that recombinant canine adenovirus type-2 expressing TgROP16 and TgROP18 provides partial protection against acute T. gondii infection in mice, and indicate that adenovirus vectors may be potentially useful in the development of an effective vaccine against T. gondii infection [21,22]. The mucosal immune system consisting of specialized epithelial cells can trigger both humoral and cell immune responses when antigens are administered with appropriate adjuvants or attenuated live vaccines via mucosal routes (oral, nasal, sublingual, ocular, genital, or rectal) [18,23].…”

Section: Introductionmentioning

confidence: 99%

Vaccination with recombinant adenovirus expressing multi-stage antigens ofToxoplasma gondiiby the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes

Wang

Yin

et al. 2017

Parasite

View full text Add to dashboard Cite

Toxoplasmosis caused by Toxoplasma gondii, an obligate intracellular protozoan, is a cause of congenital disease and abortion in humans and animals. Various vaccination strategies against toxoplasmosis in rodent models have been used in the past few decades; however, effective vaccines remain a challenge. A recombinant adenovirus vaccine expressing ubiquitin-conjugated multi-stage antigen segments (Ad-UMAS) derived from different life-cycle stages of T. gondii was constructed previously. Here, we compared the immune responses and protection effects in vaccination of mice with Ad-UMAS by five vaccination routes including intramuscular (i.m.), intravenous (i.v.), subcutaneous (s.c.), intraoral (i.o.), and intranasal (i.n.). Much higher levels of T. gondii-specific IgG and IgA antibodies were detected in the sera of the intraoral and intranasal vaccination groups on day 49 compared with controls (p < 0.05). The percentages of CD8+ T-cells in mice immunized intranasally and intraorally were larger than in mice immunized intramuscularly (p < 0.05). The highest level of IL-2 and IFN-γ was detected in the group with nasal immunization, and splenocyte proliferation activity was significantly enhanced in mice immunized via the oral and nasal routes. Furthermore, the higher survival rate (50%) and lower cyst numbers observed in the intraoral and intranasal groups all indicate that Ad-UMAS is far more effective in protecting mice against T. gondii infection via the mucosal route. Ad-UMAS could be an effective and safe mucosal candidate vaccine to protect animals and humans against T. gondii infection.

show abstract

Protective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice

Cited by 22 publications

References 37 publications

Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines

Evaluation of protective efficacy of three novel H3N2 canine influenza vaccines

Transcriptome Analysis of Testes and Uterus: Reproductive Dysfunction Induced by Toxoplasma gondii in Mice

Vaccination with recombinant adenovirus expressing multi-stage antigens ofToxoplasma gondiiby the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes

Contact Info

Product

Resources

About